Literature DB >> 16012190

Is the GABA B heterodimer a good drug target?

Fiona H Marshall1.   

Abstract

GABA(B) receptors are a member of the G protein-coupled family of receptors which are generally considered to be excellent drug targets. Cloning of the GABA(B) receptor demonstrated that, unlike other G protein-coupled receptors, it is an obligate heterodimer. Drugs acting at GABA(B) receptors have the potential to treat a wide variety of diseases. Activation of the receptors may have utility in the treatment of pain, drug-dependence, and anxiety, whereas blockade of receptors may have benefit in cognitive disorders and depression. To date, development of drugs has been hampered by the lack of receptor subtypes and the inability to separate therapeutic benefit from side effects such as sedation. Recently, novel compounds that act via an allosteric mechanism have been identified and are providing hope that future drugs may be developed that target this receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012190     DOI: 10.1385/JMN:26:2-3:169

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  49 in total

Review 1.  Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives.

Authors:  Fabrizio Gasparini; Rainer Kuhn; Jean-Philippe Pin
Journal:  Curr Opin Pharmacol       Date:  2002-02       Impact factor: 5.547

2.  Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function.

Authors:  T Galvez; B Duthey; J Kniazeff; J Blahos; G Rovelli; B Bettler; L Prézeau; J P Pin
Journal:  EMBO J       Date:  2001-05-01       Impact factor: 11.598

Review 3.  RAMPs: accessory proteins for seven transmembrane domain receptors.

Authors:  S M Foord; F H Marshall
Journal:  Trends Pharmacol Sci       Date:  1999-05       Impact factor: 14.819

4.  Distribution of a GABAB-like receptor protein in the rat central nervous system.

Authors:  K J Charles; A R Calver; S Jourdain; M N Pangalos
Journal:  Brain Res       Date:  2003-11-07       Impact factor: 3.252

Review 5.  GPCR drug discovery through the exploitation of allosteric drug binding sites.

Authors:  Stephen Rees; Dwight Morrow; Terry Kenakin
Journal:  Recept Channels       Date:  2002

6.  The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor.

Authors:  Virginie Binet; Carole Brajon; Laurent Le Corre; Francine Acher; Jean-Philippe Pin; Laurent Prézeau
Journal:  J Biol Chem       Date:  2004-05-04       Impact factor: 5.157

7.  Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501.

Authors:  S Urwyler; J Mosbacher; K Lingenhoehl; J Heid; K Hofstetter; W Froestl; B Bettler; K Kaupmann
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

8.  Opposite effects of GABAB receptor antagonists on absences and convulsive seizures.

Authors:  M Vergnes; A Boehrer; S Simler; R Bernasconi; C Marescaux
Journal:  Eur J Pharmacol       Date:  1997-08-13       Impact factor: 4.432

Review 9.  Multiple GABAB receptors.

Authors:  G Bonanno; M Raiteri
Journal:  Trends Pharmacol Sci       Date:  1993-07       Impact factor: 14.819

Review 10.  Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel?

Authors:  James Wise; Jeffrey L Conklin
Journal:  Curr Gastroenterol Rep       Date:  2004-06
View more
  9 in total

1.  Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA B receptors.

Authors:  Sébastien Guery; Philipp Floersheim; Klemens Kaupmann; Wolfgang Froestl
Journal:  Bioorg Med Chem Lett       Date:  2007-09-08       Impact factor: 2.823

2.  The oligomeric state sets GABA(B) receptor signalling efficacy.

Authors:  Laëtitia Comps-Agrar; Julie Kniazeff; Lenea Nørskov-Lauritsen; Damien Maurel; Martin Gassmann; Nathalie Gregor; Laurent Prézeau; Bernhard Bettler; Thierry Durroux; Eric Trinquet; Jean-Philippe Pin
Journal:  EMBO J       Date:  2011-05-06       Impact factor: 11.598

3.  The triplet puzzle of homologies in receptor heteromers exists also in other types of protein-protein interactions.

Authors:  Alexander O Tarakanov; Kjell G Fuxe
Journal:  J Mol Neurosci       Date:  2011-03-18       Impact factor: 3.444

Review 4.  Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.

Authors:  Leonardo F Fontenelle; Sanne Oostermeijer; Ben J Harrison; Christos Pantelis; Murat Yücel
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 5.  Clinical potential of GABAB receptor modulators.

Authors:  Jennifer Ong; David I B Kerr
Journal:  CNS Drug Rev       Date:  2005

6.  Paired-pulse inhibition in the auditory cortex in Parkinson's disease and its dependence on clinical characteristics of the patients.

Authors:  Elena Lukhanina; Natalia Berezetskaya; Irina Karaban
Journal:  Parkinsons Dis       Date:  2010-11-01

Review 7.  Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia.

Authors:  Kjell Fuxe; Daniel Marcellino; Amina S Woods; Leo Giuseppina; Tiziana Antonelli; Luca Ferraro; Sergio Tanganelli; Luigi F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2009-01-21       Impact factor: 3.575

8.  Antitussive effects of the peripherally restricted GABAB receptor agonist lesogaberan in guinea pigs: comparison to baclofen and other GABAB receptor-selective agonists.

Authors:  Brendan J Canning; Nanako Mori; Anders Lehmann
Journal:  Cough       Date:  2012-10-01

9.  The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components.

Authors:  Dasiel O Borroto-Escuela; Ismel Brito; Wilber Romero-Fernandez; Michael Di Palma; Julia Oflijan; Kamila Skieterska; Jolien Duchou; Kathleen Van Craenenbroeck; Diana Suárez-Boomgaard; Alicia Rivera; Diego Guidolin; Luigi F Agnati; Kjell Fuxe
Journal:  Int J Mol Sci       Date:  2014-05-14       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.